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Sir,
I read with great interest the article by Hurst et al (2007), which
was recently published in the Br J Cancer. The authors described
elevated serum concentration of matrix metalloproteinase 9 (MMP-
9) in patients with colorectal neoplasia compared with the MMP-9
concentration in symptomatic patients without non-neoplastic
conditions. On the basis of this result of increased serum MMP-9
concentration the authors developed a logistic regression model
including age, sex, smoking history, abdominal pain, and weight loss
as additional factors for the prediction of malignant colorectal
disease. The authors concluded that increased serum MMP-9
concentrations could be useful to stratify patients into those with
low- and high-risk of malignancy to spare patients unnecessary
colonoscopy. Some of the authors of this article already elaborated
detailed study protocols including sample size calculation, potential
selection bias, confounders, methods of analyses study protocols to
evaluate the potential of serum MMP-9 as a screening test for
colorectal cancer (Ryan et al,2 0 0 6 ;W i l s o net al, 2006). Apparently
based on the pilot data described in the mentioned report of Hurst
et al (2007) and the prevalence data of colon cancer, it was calculated
that 23100 people from 29 practices have to be recruited to identify
the 700 participants needed for this study (Wilson et al, 2006).
However, I have the impression that the authors overlooked the
fundamental problem of pre-analytical conditions for accurate
MMP-9 measurements. They did not pay attention to the potential
pre-analytical pitfall of blood sampling to measure true concentra-
tions of circulating MMP-9 as serum instead of plasma was used for
MMP-9 measurements and also recommended for this ambitious
study. The misuse of serum as sample for determining circulating
MMP-9 in peripheral blood has been frequently criticised both
in analytical and clinical journals (Jung et al, 1998; Makowski
and Ramsby, 2003; Mannello et al, 2003, 2007; Meisser et al,
2005; Souza-Tarla et al, 2005; Zucker and Cao, 2005). In addition,
technical details of serum sampling and handling procedure, for
example the time between phlebotomy and centrifugation of blood
samples, should be described because they are critical determinants
that could affect the concentrations of MMP-9 (Jung et al, 2005;
Meisser et al, 2005; Mannello and Tonti, 2007).
To illustrate that problem comparative MMP-9 measurements
were performed in serum and plasma samples that were obtained
under different collection conditions. For that purpose, blood
samples from 10 healthy adults were simultaneously collected in
differently prepared plastic tubes (Monovette Systems, Sarstedt
AG, Nu ¨mbrecht, Germany) and centrifuged at 1600g at 41C for
15min within 30min after venepuncture. Tubes either with kaolin-
coated granulate as clot activator or without additive were used to
prepare serum after enhanced coagulation (serum
(þ)) and native
serum (serum
( )), respectively whereas tubes coated with lithium
heparin, sodium citrate or dipotassium EDTA were used to collect
plasma samples. The supernatants were carefully removed and
stored at  801C until analysis. MMP-9 was measured in duplicates
with the Fluorokine MultiAnalyte Profiling assay (R&D Systems,
Minneapolis, MN, USA) detecting pro-, mature, and TIMP
complexed MMP-9 according to the note of the producer. The
coefficient of variation calculated from the duplicate values was
9.7%. The striking effect of sample collection on the MMP-9
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Figure 1 Relative concentrations of MMP-9 in serum and plasma
samples. Percentage values (medians with interquartile ranges) of MMP-9
concentrations in serum and plasma samples simultaneously collected from
10 healthy adults were related to the values in serum
(þ) samples (median:
536mgl
 1; interquartile ranges: 384–692mgl
 1) that were taken as 100%.
Further details see text. Serum
(þ) and serum
( ): serum prepared with and
without clot activator (kaolin-coated granulate).
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www.bjcancer.comconcentrations is presented as percentage data related to values
obtained in serum
(þ) collected with clot activator (Figure 1).
Higher MMP-9 concentrations were observed in serum than in
plasma. In addition, the kind of serum sampling procedure with or
without clot activator was important. The concentrations found
in serum
(þ) samples collected with clot activator were about
3–4 times higher compared with those in serum
( ) samples
collected without clot activator. However, also the MMP-9
concentrations in serum
( ) samples collected without clot acti-
vator corresponding to serum collected in plain tubes using the
Vacutainer system by Hurst et al (2007) were 3–5 times higher
than in heparin or citrate plasma. All these data show that serum
MMP-9 concentrations do not correspond to the real circulating
concentrations of MMP-9 in blood because the anticoagulants do
not affect the recovery of MMP-9 in samples (Jung et al, 1998).
Platelets and leukocytes abundantly contain MMP-9 among other
proteases (Murphy et al, 1977; Cooper et al, 1985; Opdenakker
et al, 2001; Sheu et al, 2004; Santos-Martinez et al, 2008). The
increased MMP-9 concentration observed in serum may be due
both to release of MMP-9 during coagulation from the blood
cells and its secretion that is induced by the clot activator itself
(Mannello and Tonti, 2007; Mannello et al, 2007). Thus, it can be
assumed that this high unspecific background concentration of
MMP-9 in serum probably impairs the potential diagnostic/
prognostic performance of this parameter. Recent studies
confirmed that plasma MMP-9 had better diagnostic accuracy
than serum MMP-9 (Jung et al, 2001; Wu et al, 2007). Also the
consistent use of serum collected under identical conditions was
obviously not suitable to circumvent that effect.
In conclusion, serum collected either with or without clot
activator should not be considered as an appropriate sample for
determining circulating MMP-9. Pre-analytical conditions of
sample collection and handling have to be clarified before the
diagnostic or prognostic performance of a corresponding marker
should be explored in clinical trials (Mannello et al, 2005; Lomholt
et al, 2007). It may be advisable to re-consider the sample
collection procedure for the planned studies. Citrate plasma has
been suggested to be the sample of choice for measuring
circulating MMP-9 (Makowski and Ramsby, 2003; Mannello
et al, 2003; Meisser et al, 2005; Gerlach et al, 2005).
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